Seamless Therapeutics Appoints Alvin Shih To Board Of Directors To Strengthen Leadership Team

Seamless Therapeutics announced today the appointment of Alvin Shih, M.D., M.B.A., as an Independent Director to its Board of Directors. Dr. Shih is a highly experienced physician and biotech executive with a strong background in drug development and leadership across a range of therapeutic areas, particularly in rare diseases. His addition to the Board comes at a key time for Seamless Therapeutics as the company continues to advance its pipeline of programmable recombinase-based therapies toward clinical development.

Dr. Shih currently serves as the Chief Executive Officer of Imbria Pharmaceuticals, a clinical-stage biotechnology company focused on developing innovative treatments for patients with cardiometabolic disorders. Throughout his career, he has held several leadership positions in both public and private biotech companies. He was previously the President and CEO of Catamaran Bio and the CEO of Disarm Therapeutics, a neuroscience company that was acquired by Eli Lilly in 2020. 

Before that, he led Enzyvant Therapeutics, a company dedicated to regenerative medicine approaches for rare diseases. Earlier in his career, Dr. Shih served as Head of R\&D at Retrophin and as Chief Operating Officer of the Pfizer Rare Disease Research Unit. His professional journey began in management consulting, with roles at McKinsey & Company and L.E.K. Consulting, where he supported healthcare and life sciences clients. 

Adam Rosenberg, Independent Chairman of the Board of Seamless Therapeutics, stated, “Alvin’s demonstrated success in enabling biotech companies to reach the next stages of their therapeutic and corporate development will be an invaluable asset supporting the maturation of the company and its discovery pipeline. His clinical expertise and business acumen will strengthen Seamless’ position to execute on this potentially transformative platform to achieve breakthroughs in genetic medicine.”

Albert Seymour, Ph.D., Chief Executive Officer of Seamless Therapeutics, mentioned, “Our goal is to be a global leader in next-generation gene editing therapeutics that can meet the high unmet need of patients with inherited diseases. Alvin’s depth of knowledge in developing first-in-class treatments positions him to provide important strategic perspectives to our development and commercial strategies. With upcoming in vivo data further validating the potential of our precision gene editing approach, we look forward to working with our experienced Board members to realize the full potential of our groundbreaking technologies.”

Dr. Shih holds a medical degree from the University of Alabama School of Medicine and an M.B.A. from the Kellogg School of Management at Northwestern University. In addition to his new role at Seamless Therapeutics, he serves as a director on the boards of several venture-backed, public, and nonprofit life sciences organizations, including Zevra Therapeutics and Tenza Bio. With Dr. Shih’s broad industry experience and deep understanding of rare disease drug development, Seamless Therapeutics expects his guidance will be instrumental as the company prepares to bring its novel therapeutic platform into the clinic.